Compare McKesson Corporation (MCK) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Union Pacific Corporation — how do they compare? McKesson Corporation trades at $832.45 (market cap $98.51B), while Union Pacific Corporation trades at $298 (market cap $179.15B). The key difference: Union Pacific Corporation is the larger of the two by market cap, and Union Pacific Corporation pays the higher dividend (1.83%). Which is the better fit depends on your goals.
| MCK | UNP | |
|---|---|---|
Market Cap | $98.51B | $179.15B |
Sector | Health | Industrials |
52-Week High | $995.69 | $301.75 |
52-Week Low | $659.01 | $214.91 |
Enterprise Value | $103.15B | $209.62B |
Dividend Yield | 0.39% | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Union Pacific (UNP) trades at $296.00, down 1.91% amid mixed technical signals. The stock shows strong fundamentals with 29.2% net margins and 40.69% ROE, while Q1 2026 earnings beat expectations. Analysts maintain a bullish consensus with a $311.07 price target. Recent news highlights the Norfolk Southern merger progress and upcoming Q2 earnings, with institutional buying supporting positive sentiment despite regulatory and legal overhangs.
Outlook remains positive given earnings momentum and operational efficiency, but risks include merger regulatory scrutiny, pending class action litigation, and cyclical freight demand. The stock offers value near consensus targets with dividend growth, though investors should weigh execution risks against solid profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
